Last reviewed · How we verify
Generic A
At a glance
| Generic name | Generic A |
|---|---|
| Also known as | Metoprolol extended-release (ER) |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effects of 5G Radiation on Skin (NA)
- Transdiagnostic Metacognitive Therapy Compared to Disorder-Specific Cognitive-Behavioral Therapy for Anxiety Disorders (NA)
- A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
- Psychological and Lifestyle Factors That Predict Adherence of Multi-domain Interventions for Promoting Brain Health (NA)
- Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Hormone Receptor-positive / Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Patients: A Comparative Study
- Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults (PHASE1)
- Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 (PHASE2)
- A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic A CI brief — competitive landscape report
- Generic A updates RSS · CI watch RSS
- University of Florida portfolio CI